Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript
Source: SeekingAlpha
2026-04-08 18:16:08 ET
Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights April 8, 2026 1:00 PM EDT...
Read the full article on Seeking Alpha
For further details see:
Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript
Autolus Therapeutics plc
NASDAQ: AUTL
AUTL Trading
20.32% G/L:
$1.895 Last:
1,717,980 Volume:
$1.62 Open:
AUTL Latest News
May 14, 2026 07:00:00 am
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesMay 05, 2026 07:00:00 am
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026April 29, 2026 04:05:00 pm
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost ReductionAUTL Stock Data
$387,238,481
109,839,996
N/A
49
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
